ImmuPharma PLC's (LON:IMM) Tim McCarthy caught up with Proactive London's Andrew Scott soon after the firm announced it had raised £1.5mln from a share subscription to fund an expansion of its research & development programmes.
The funding comprises a £200,000 share subscription by the company’s president and chief scientific officer Robert Zimmer as well as £1.3mln from Lanstead Capital - an institutional investor and significant shareholder in the business.
ImmuPharma's strengthening its advisory team for a phase III trial of its Lupuzor lupus treatment and has also planned a proof of concept study for Lupuzor in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
